MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

MDxHealth reported Q2 revenue of $27.2M (+16% YoY) and a 14% sequential increase (+$3.3M), but profitability remains pressured: operating loss widened to $5.1M and net loss rose 36% to $9.5M, with adjusted EBITDA at -$2.3M. Gross margin fell to 65.7% (down 290 bps YoY) due to a tissue-vs-liquid mix shift after the ExoDx acquisition, while the company expects higher costs to be absorbed as it targets return to positive adjusted EBITDA exiting 2026. The firm reiterated FY2026 revenue guidance of $110M–$115M (+20%–+26%) and raised $20M via a registered direct placement (no warrants), bringing pro forma cash to $39.2M as it winds down Resolve and continues AI/clinical data efforts for GPS.

Analysis

This is less a clean acceleration story than a reset after management removed a distraction and re-routed sales effort back to the core franchise. The sequential improvement is real, but the market should treat part of it as catch-up rather than a new run-rate, which matters because the next two quarters have to prove that volume can hold without the one-time benefit of customer migration and organizational stabilization.

The bigger economic signal is balance-sheet repair via dilution, not operating leverage. Cash now looks adequate for a few quarters, but the financing tells you the business is still not self-funding, so every revenue miss will flow quickly into equity value. Gross margin pressure from mix plus higher acquired opex is the key second-order risk: if liquid growth outpaces tissue, the top line can look healthy while EBITDA remains stuck.

Consensus may be too eager to extrapolate a straight-line back half. The contrarian upside case is a sharp squeeze if the company prints another clean quarter and shows genuine pathway adoption, but the burden of proof is high; the near-term falsifier for a bearish view is a Q3 revenue step-up with margin recovery and clear progress toward breakeven. Over 6-18 months, the stock likely remains a financing-and-execution trade unless reimbursement and share gains become visibly durable.

Key Decisions for Investors

• Short MDXH on strength into the next 2-6 weeks; use a small position given microcap liquidity. Risk/reward is attractive if the market is pricing a smooth 2H ramp that does not materialize. Cover if Q3 revenue exceeds ~$28.5M and adjusted EBITDA improves meaningfully quarter over quarter.
• Pair trade: long NTRA / short MDXH for 1-3 months as a relative-quality expression in genomics/oncology diagnostics. NTRA has scale, reimbursement diversification, and less dilution risk; MDXH still needs proof that growth is self-sustaining. Exit if MDXH demonstrates two consecutive quarters of >10% sequential growth.
• If forced to own MDXH, wait for the next print rather than buying now. The cleaner entry is after Q3 if revenue is linear and gross margin stabilizes above current levels; otherwise the dilution overhang likely caps multiple expansion.
• Watch item: if management revises FY26 revenue back above $115M or confirms EBITDA breakeven earlier than year-end, cover any short immediately. That would imply the integration drag is fading faster than expected and would reset the bear case.